Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
3 search results for:

Umbralisib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 02-03-2018 | Hematologic cancers | News | Article

    Next-generation PI3Kδ inhibitor umbralisib warrants further investigation

    The phosphatidylinositol 3-kinase isoform p110δ inhibitor umbralisib has shown preliminary activity against relapsed or refractory hematologic malignancies, with fewer autoimmune-like toxicities than other drugs in its class, researchers report.

    Published in:
    Lancet Oncol 2018; Advance online publication
  2. 17-10-2018 | Chronic lymphocytic leukemia | News | Article

    Duvelisib offers treatment alternative for patients with CLL/SLL

    . © 2018 Springer Healthcare part of the Springer Nature group See also:  Next-generation PI3Kδ inhibitor umbralisib warrants further investigation  

    Published in:
    Blood 2018; doi:10.1182/blood-2018-05-850461
  3. 03-08-2018 | Hodgkin lymphoma | News | Article
    News in brief

    ‘Reassuring’ childbirth rate reported for Hodgkin lymphoma survivors

    See also:  First-line brentuximab vedotin approved for advanced Hodgkin lymphoma Brentuximab vedotin may improve outcome in advanced Hogkin lymphoma Next-generation PI3Kδ inhibitor umbralisib warrants further investigation

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.